Publications by authors named "Alan D Borthwick"

Claim this Profile
F
Functional Alternatives to Alcohol.
David J Nutt, Robin J Tyacke, Meg Spriggs, Vanessa Jacoby, Alan D Borthwick

Nutrients· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review.
Alan D Borthwick, Maria B Goncalves, Jonathan P T Corcoran

Bioorg Med Chem· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury" [Bioorg. Med. Chem. Lett. 29(8) (2019) 995-1000].
Maria B Goncalves, Earl Clarke, Christopher I Jarvis, S Barret Kalindjian, Thomas Pitcher, Alan D Borthwick

Bioorg Med Chem Lett· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.
Maria B Goncalves, Earl Clarke, Christopher I Jarvis, S Barret Kalindjian, Thomas Pitcher, Alan D Borthwick

Bioorg Med Chem Lett· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.
Earl Clarke, Christopher I Jarvis, Maria B Goncalves, S Barret Kalindjian, David R Adams, Alan D Borthwick

Bioorg Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluparoxan: A Comprehensive Review of its Discovery, Adrenergic and CNS Activity and Treatment of Cognitive Dysfunction in Central Neurodegenerative Diseases.
Alan D Borthwick

Mini Rev Med Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,5-diketopiperazines in food and beverages: Taste and bioactivity.
Alan D Borthwick, Neil C Da Costa

Crit Rev Food Sci Nutr· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,5-Diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products.
Alan D Borthwick

Chem Rev· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
Alan D Borthwick, John Liddle, Dave E Davies, Anne M Exall, Christopher Hamlett

J Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor.
Alan D Borthwick, John Liddle

Med Res Rev· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral oxytocin antagonists.
Alan D Borthwick

J Med Chem· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.
Savvas Kleanthous, Alan D Borthwick, David Brown, Cynthia L Burns-Kurtis, Matthew Campbell

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of GSK221149A: a potent and selective oxytocin antagonist.
John Liddle, Michael J Allen, Alan D Borthwick, David P Brooks, David E Davies

Bioorg Med Chem Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs.
Robert J Young, Alan D Borthwick, David Brown, Cynthia L Burns-Kurtis, Matthew Campbell

Bioorg Med Chem Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Robert J Young, Alan D Borthwick, David Brown, Cynthia L Burns-Kurtis, Matthew Campbell

Bioorg Med Chem Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.
Gerald P McCafferty, Mark A Pullen, Charlene Wu, Richard M Edwards, Michael J Allen, Alan D Borthwick

Am J Physiol Regul Integr Comp Physiol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.
Chuen Chan, Alan D Borthwick, David Brown, Cynthia L Burns-Kurtis, Matthew Campbell

J Med Chem· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
Robert J Young, Matthew Campbell, Alan D Borthwick, David Brown, Cynthia L Burns-Kurtis

Bioorg Med Chem Lett· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.
Alan D Borthwick, Dave E Davies, Anne M Exall, Richard J D Hatley, Jennifer A Hughes

J Med Chem· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
Alan D Borthwick, Dave E Davies, Anne M Exall, David G Livermore, Steve L Sollis

J Med Chem· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of translactam HCMV protease inhibitors as potent antivirals.
Alan D Borthwick

Med Res Rev· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: Identification, stereochemistry and initial SAR.
Paul G Wyatt, Michael J Allen, Alan D Borthwick, Dave E Davies, Anne M Exall

Bioorg Med Chem Lett· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of pyrrolidine-5,5'-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability.
Alan D Borthwick, Dave E Davies, Peter F Ertl, Anne M Exall, Terry M Haley

J Med Chem· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability.
Alan D Borthwick, Anne M Exall, Terry M Haley, Deborah L Jackson, Andrew M Mason

Bioorg Med Chem Lett· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality.
Alan D Borthwick, Andrew J Crame, Peter F Ertl, Anne M Exall, Terry M Haley

J Med Chem· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis